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INTRODUCTION: 
The goal of this study has been to describe the epidemiology of vestibular schwannoma 
and explore potential risk factors for this tumor. Other goals of this study have been to 
look at the function and quality of life of patients compared with the general US 
population as well as outcomes after radiosurgery treatment.    
 
METHODS: 
A 1:1 matched case-control study was designed. Odds ratios were established based 
on multivariate conditional logistic regression models. Quality of life was measured with 
the Short-Form 36 Item Health Survey v.2 and audiograms measuring the non-tumor 
ear were collected and analyzed for comparison with normative US population data. 
 
RESULTS: 
Average age at diagnosis was 53 (StDev±12). More than 90% of the participants were 
Caucasian. Patients were evenly distributed by gender. Family history of cancer, a 
history of hay fever, managerial and professional occupations, and frequent dental x-
rays were found to have an increased association with acoustic neuroma in multivariate 
models. Tobacco use and di abetes were found to have a s ignificantly decreased 
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association with acoustic neuroma in multivariate models. Patients did not have 
significantly different quality of life scores or audiogram measurements of their non-
tumor ear when compared to age-matched US population norms. 
 
CONCLUSIONS: 
Patients with (AN) have the profile of being Caucasian, either gender, in their 50-60’s, 
and working in managerial, professional jobs. Hay fever, family history of cancer, and 
frequent dental x-rays are strongly associated with an i ncrease risk of acoustic 
neuromas. Tobacco use and diabetes demonstrate a protective effect, although the 
mechanism of this is poorly understood. Patients maintain a quality of life similar to the 
US population. Acoustic neuromas do not affect hearing in the non-tumor ear. 
 
PUBLIC HEALTH SIGNIFICANCE: 
The epidemiology and r isk factors of vestibular schwannoma are poorly understood. 
Continued research in this area will help to develop an understanding of brain tumor 
etiology and the role of potential carcinogens in the environment. Functional research 
will help to look at the role of surgical treatments and the degree of morbidity in these 
patients.   
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1.0  INTRODUCTION 
There is little known about the etiology of Vestibular schwannomas (also known as 
acoustic neuroma). This may, in part, be due to its relatively rare occurrence and benign 
growth pattern which makes it elusive and difficult to study. There are two causes of 
acoustic neuroma that are well understood. These are the hereditary bilateral form 
caused by a gene deletion that is known as neurofibromatosis type II (an NF-2 genetic 
mutation of the long arm of chromosome 22), as well as exposure to ionizing radiation. 
Neurofibromatosis causes damage to the tumor suppressing protein 
neurofibromin which allows proliferation of tumor cells in nervous system tissue. 
Interestingly, genetic mutations of chromosome 22 have been found in a large 
proportion of the sporadic (unilateral) acoustic neuromas upon molecular genetics 
evaluation. 1 These patients may not have the systemic genetic mutations found in 
neurofibromatosis type-2 but they do have similar gene deletions within the tumor itself.  
Significant associations have been fairly well established between ionizing 
radiation exposure and long-term risk of developing central nervous system neoplasm. 
These exposures include large nuclear events like the atomic bomb2,3 and radiation 
treatments to the head and neck. 4-6  
Other exposures have been looked at as well such as radiofrequency and mobile 
phone technology, allergy and i mmunologic diseases, loud noise, and v arious other 
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demographic and environmental risk factors. These studies have shown inconclusive 
results and ar e often limited by several factors including small sample size and 
insufficient power, potential for study bias (including recall bias, misclassification bias, 
and diagnostic bias), non-validated and subjective data collection, and short study 
periods. 
1.1 BACKGROUND 
1.1.1 Biology 
The acoustic nerve is one of twelve cranial nerves that emerge directly from the 
brainstem. It is also known as the eighth cranial nerve (eighth out of the twelve cranial 
nerves) or the vestibulocochlear nerve. It arises in the cerebellopontine area and travels 
through the internal auditory canal. It then separates into three branches at the internal 
auditory meatus. The superior vestibular portion innervates the vestibular utricle, the 
inferior vestibular portion innervates the vestibular saccule and the cochlear nerve 
portion innervates the cochlea.  
Vestibular schwannomas tend to arise from the Schwann cells of the vestibular 
portion of the nerve just at the internal auditory meatus. The Schwann cells are 
responsible for producing the myelin sheath that surrounds the axon of a nerve. The 
tumor begins to grow through the boney portion of the internal auditory canal. Tumors 
can then continue to grow through the internal auditory canal into the cerebellopontine 
area. 
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Acoustic neuromas can develop bilaterally in people with the hereditary form but 
normally they develop unilaterally in people with the common, spontaneous form. The 
Vestibulocochlear nerve has several components. It is best known for its role in hearing 
and balance. In rare instances, acoustic neuromas can have a m alignant 
transformation. Generally, though, acoustic neuromas are benign and s low growing 
lesions that tend to begin in the vestibular portion of the nerve and can affect several 
aspects of function. Typically the earliest signs and s ymptoms of a per son with an 
acoustic neuroma are either hearing loss on the affected side, balance problems, 
vertigo, or a p erception of noise in the ear known as tinnitus. These can occur as 
isolated symptoms or a combination of several.  
If not treated early enough, the tumor can continue to grow and impinge on the 
surrounding nerves such as the trigeminal nerve and the facial nerve and even the 
glossopharyngeal nerve. This can cause symptoms such as facial numbness, facial 
pain, and facial weakness as well as difficulty swallowing. Very large acoustic neuromas 
can even begin to compress the brain stem and the fourth ventricle causing an 
obstruction of cerebrospinal fluid outflow. This can cause severe symptoms such as 
ataxia and hydrocephalus and can eventually lead to death. 
1.1.2 Incidence and Public Health Concern 
Acoustic neuromas are tumors originating from the eighth cranial nerve also known as 
the acoustic nerve. They occur just as often in women and i n men and they tend to 
begin to grow in people around the age of 50.7-9 They have, though been detected in 
people as young as their twenties and even teens. Historically, acoustic neuromas have 
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an incidence rate of just under 1 i n 100,000 persons per year.7,8 They account for 
approximately 6% of all brain tumors.9 They account for over 90% of all nerve sheath 
tumors.7  
Recent prevalence studies have looked at the prevalence of undiagnosed 
acoustic neuromas. The authors searched imaging databases looking specifically for 
acoustic neuromas that were found incidentally on s cans that were performed for 
reasons other than audiovesibular abnormalities. The prevalence of unsuspected 
acoustic neuroma was found to be between 2 to 7 per 10,000 people, respectively.(9,10) 
Natural history has shown the proportion of acoustic neuromas that will continue 
to grow to be at a rate of about 17% for intrameatal tumors and 29% for extrameatal 
tumors over the course of about five years if left for observation (cohort of 552 patients 
under observation management).11 These growth proportion rates vary greatly in the 
literature, though; between 14% all the way up to 74% looking up to five years of follow 
up.1213Some studies have even projected long-term growth to be up to 87%.14  
A Danish study looked at the increasing incidence of Acoustic Neuroma in 
Denmark over the past few decades. Denmark has an incidence rate of acoustic 
neuroma that has been increasing from 5.1 per million per year in 1976 to 19.3 per 
million per year in 2001.15 The study attributes the rate increase to the increase in better 
imaging technology such as CT and MRI. Interestingly though, the median age at 
diagnosis remains at 55 throughout this period. Also, the smaller tumors that are being 
picked up thanks to better imaging are being found in older not younger patients.  
Tos, M (2004) has argued that the median size of acoustic neuroma at diagnosis 
has significantly decreased over the years in probable accordance with increased 
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imaging technology. He has also argued that the mean diagnostic delay for acoustic 
neuromas has been decreasing over the years.8He puts the mean patient and physician 
combined diagnostic delay as decreasing from 13 years to 7 years from the late 
seventies to the late nineties. As much as 22% of acoustic neuromas were diagnosed 
within the first symptomatic year. Stangerup,S.E. (2004) found in his study, the mean 
age at diagnosis remained stable and is even increasing.  
 There is evidence that the true incidence rate has been climbing over the past 
two decades. J M Propp, et al. (2006)7 showed this by looking at data from the central 
brain tumor registry of the United States (CBTRUS) and from the Los Angeles County 
cancer surveillance program (LACCSP). She showed that statistically significant trends 
have been observed in vestibular schwannoma incidence of about 14% increase per 
year between 1992-1999 from the CBTRUS data. The LACCSP showed about a 6% 
increase in incidence between 1992-1998. Some have argued that this rise is due i n 
part to the introduction of better diagnostic imaging such as CT and MRI. Again, she 
points out that the recent data should not have been affected since it covers the period 
after 1992 which would have already gone past the peak of CT/MRI availability. We do 
not see a sharp peak in incidence when looking at LACCSP data going back to the 
1970’s and early 80’s when we would have expected it since this was during the 
introduction period of CT and MRI.7,8 
J M Propp, et al. (2006) also analyzed a sub grouping of vestibular vs. non-
vestibular schwannomas. While vestibular schwannomas have showed a s ignificant 
increase in both CBTRUS and LACCSP analyses, non-vestibular schwannomas 
showed no significant increase in the LACCSP and even showed a decrease in the 
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CBTRUS analyses. This difference in incidence rates brings into question whether in 
fact this is an artifact of better diagnostic modalities.  
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2.0  EPIDEMIOLOGY AND ENVIRONMENTAL RISK FACTORS ASSOCIATED 
WITH VESTIBULAR SCHWANNOMA 
2.1 INTRODUCTION 
There is little known about the etiology of Vestibular schwannomas. There are only two 
causes of acoustic neuroma that are well understood. There is the hereditary bilateral 
form caused by a gene deletion; neurofibromatosis type II (an NF-2 genetic mutation of 
the long arm of chromosome 22), as well as exposure to ionizing radiation.    
Acoustic neuromas are tumors originating from the eighth cranial nerve also 
known as the acoustic nerve. They occur just as often in women and in men and they 
tend to begin to grow in people around the age of 50.7-9 They have, though, been 
detected in people as young as their twenties and even teens. Historically, acoustic 
neuromas have an incidence rate of just under 1 LQ 100,000 persons per 
year.7,8(Although there is evidence that this incidence has been rising)7 They account 
for approximately 6% of all brain tumors.9 They account for over 90% of all nerve sheath 
tumors.7  
The goal of this study has been to explore some of the potential risk factors that 
are not yet well understood. We drew from our sample of patients who have this tumor 
to investigate several exposures of interest. We have previously looked at low-dose 
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radiation exposure and mobile phone technology as these have shown conflicting 
results in the literature.16Only a f ew studies by Hardell et al17,18have shown any 
significant association. Several studies have shown some associations between 
acoustic neuroma and atopic disease.19-21We looked at allergy and i mmunologic 
diseases as a potential cause for neoplastic changes. Two studies have shown a 
decreased risk of acoustic neuroma in patients using tobacco22,23 and we investigated 
smoking risk in this study. We evaluated loud noise and acoustic trauma as this has 
also shown conflicting results.20,24-27We described the various demographics of acoustic 
neuroma as well as lifestyle habits and occupational history. 
2.2 METHODS 
2.2.1 Design 
A hospital based case-control study design was used. 1:1 matching was performed 
based on age (+/- 5 years) and gender. Recruitment goals were based on sample size 
calculations for appropriate power. Exposures were assessed based on t he date of 
diagnosis of the case participant. This study received the approval of the University of 
Pittsburgh Institutional Review Board for Human Research and informed consent was 
obtained from all study participants. 
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2.2.2 Case Recruitment 
Cases were recruited from the University of Pittsburgh’s Gamma Knife® Radiosurgery 
database. Patients who were treated for acoustic neuroma between the years 1997-
2007 were solicited for participation. Geographic recruitment was limited to the North 
American continent in order to avoid an ecological bias. Patients with Neurofibromatosis 
type 2 were excluded from this study.  
Patients were contacted by written letter via the US Postal service. A 
questionnaire was mailed along with a pre-paid return envelope. Patients were given 
the option to fill out the questionnaire by hand or have it done over the telephone with a 
trained recruiter or to send it via email. A trained recruiter also checked every 
questionnaire that was completed for missing data points and contacted the participants 
via telephone to complete the necessary missing data.  
A total of 822 patients underwent SRS for acoustic neuroma between 1997-2007. 
Limiting our target cases to people residing in North America, a total of 712 mailings 
were sent out and 272 (38.2%) initially responded. Fifty six (7.9%) patients were 
reported as deceased by their family members. Sixty two (8.7%) questionnaires were 
returned by the post office with no forwarding address. A second mailing was sent out 4 
months later to the remaining patients who had n ot responded. Four hundred letters 
went out in the second mailing and 148 (37%) questionnaires were completed. In all, 
420 (59% of 712 mailings) patients completed a survey. Of the completed surveys: 406 
(96.7%) were returned via US postal service, 10 ( 2.8%) cases completed their 
questionnaire via email, and 4 ( 1.1%) questionnaires were completed via telephone 
interview at the request of the patient. 
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2.2.3 Control Recruitment 
Controls were recruited within the Neurosurgery department of the University of 
Pittsburgh. A hospital based control group was chosen from the spine clinic because 
they are mostly frequented by patients with degenerative spine disease which makes 
them less likely to have a brain tumor. The participants were approached by a trained 
recruiter who remained onsite to help the participants with any questions and to check 
the questionnaire for missing data. Controls were matched to cases based on age (+/- 5 
years) and gender. They were asked to complete the same questionnaire as the cases 
and they were instructed to recall their exposures as compared to the date of diagnosis 
of the matched case.  
Controls were excluded if they had ever been diagnosed with a brain tumor. They 
were also excluded if they displayed any of the typical acoustic neuroma symptoms 
given the remote possibility of an undiagnosed tumor. Specifically, they were excluded if 
they had symptoms of unilateral hearing loss, imbalance/vertigo/dizziness, or ringing in 
the ear that was of unknown origin or undiagnosed. Controls were also paid ten US 
dollars for their time and participation.  
Approximately 800 peopl e came through our outpatient spine clinics for 
evaluation of their degenerative spine disorders during the recruitment period. Of the 
available potential controls, approximately 200 (25%) refused (the most common reason 
was insufficient time to fill out the survey) and 222 (27.8%) initially agreed to participate 
but did not complete the survey either because they were unable to be appropriately 
matched at the time of the interview or they met the exclusion criteria. A total of 378 
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(47.3%) controls completed the questionnaire and 353 were appropriately matched to 
cases. 
2.2.4 Exposure Assessment 
Subjects were asked to complete a written questionnaire. The questionnaire included 
sections on demographics, education, and lifestyle habits. Neurosurgical history was 
taken including previous head injury and pr evious brain surgery. Medical history was 
asked with an em phasis on at opic disease, autoimmune processes, and cancer 
(including family history of cancer). Environmental exposures such as loud noise and 
chemicals were assessed.  Participants were asked if they were exposed to loud noise 
in their occupation according to how much of the time they were exposed and how often 
they used hearing protection. Recreational noise exposure was also assessed in the 
setting of loud hobbies such as instrument playing, music listening/concert attendance, 
gardening with power tools, machine shop work, target shooting/hunting, and 
ATV/motorcycle/racecar exposure. Chemical exposures were assessed and included 
tetrachloroethylene, petroleum products, vinyl chloride and chlorinated hydrocarbons, 
inks/dyes/paints/resins/solvents, pesticides/herbicides/fungicides, and h eavy 
metals/welding fumes.  
Occupational history was looked at by asking participants to list up to three 
principal lifetime occupations (including industry, occupation, and years worked). Their 
responses were then classified according to the US census coding for industries and 
occupations [www.census.gov] according to their chief lifetime occupation. Military 
service was also asked. 
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Further questions were asked regarding exposure to ionizing and no n-ionizing 
radiation. These assessments included exposure to cellular and cordless phone 
technology, hand-held electronic devices, radiation-based medical imaging, and medical 
radiation treatments. The details of our radiation analysis have been presented16 and 
will not be the main topic of discussion for this manuscript. 
2.2.5 Statistical Analysis 
A total of 420 cases and 378 controls participated. A total of 67 (16%) cases and 25 
(6.6%) controls were excluded from the final analysis due to missing data or inadequate 
matching criteria and 4 of these cases were excluded due to a history of NF-2. Upon 
conclusive 1:1 matching, 353 cases and 353 controls were included in the final data 
analysis. 
Descriptive statistics were used to describe the data including means and 
standard deviations, medians and ranges. Univariate analysis was performed using 
conditional logistic regression of matched variables to determine significant differences 
and associations between cases and controls. Odds ratios were obtained with 
associated 95% confidence intervals.  
Final models were produced with multiple conditional logistic regression 
performed for a 1:1 matched study to determine the log risk of disease. Inclusion in the 
final model was based on the univariate analysis for each variable. Variables that were 
found to be s tatistically significant in univariate analysis were included in the final 
models. Several models were developed based on clinical relevance. Results were then 
interpreted at the p<0.05 significance level. 
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2.3 RESULTS 
2.3.1 Demographics and Lifestyle Habits 
The demographic characteristics of our study participants are shown in Table 2-1. The 
average age at interview of cases and controls was 60 (standard deviation (SD) ± 12) 
and the average age at diagnosis was 53(SD±12). More than 90% of the participants 
were White or Caucasian. Acoustic neuroma cases were evenly distributed by gender 
(49.6% male) and 73.1% of cases reported some college or higher education (≥ 13 
years) compared with 49.6% of controls. More than 50% of the cases are residents of a 
tri-state area that includes Pennsylvania, Ohio, and West Virginia while more than 80% 
of the controls are. Distribution of marital status and employment status was similar 
among cases and controls. Results of the univariate analysis using conditional logistic 
regression revealed that demographic factors such as race, education, smoking, 
drinking and di abetes were found to be significantly different between cases and 
controls (p<0.05). 
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Table 2-1 Socio-demographic Factors and Lifestyle 
 Case n(%) Control n(%) 
Total  353 353 
Gender  
   Male 
   Female 
 
175 (49.6) 
178 (50.4) 
 
175 (49.6) 
178 (50.4) 
Age at Diagnosis 
   <50 
   50-65 
   >65 
 
Mean (±SD) 
 
129(36.5) 
175(49.6) 
49(13.9) 
 
53(12) 
 
134(38) 
167(47.3) 
52(14.7) 
 
53(12) 
Current Age at 
Enrollment 
Mean (±SD) 
 
 
60 (12) 
 
 
60(12) 
Residency1 
   Tri-State Area2 
   Other 
 
199 (56) 
154 (44) 
 
322 (91) 
31 (9) 
Race1 
   White 
   Other 
 
343(97.7) 
8(2.3) 
 
325(93.1) 
24(6.9) 
Marital Status 
   Single 
   Married/Partner 
   Previously Married 
 
28(7.9) 
279(79) 
46(13) 
 
28(7.9) 
259(73.4) 
66(18.7) 
Education1 
   <13 years 
   ≥13 years 
 
95(26.9) 
258(73.1) 
 
178(50.4) 
175(49.6) 
Tobacco Packyears1 
   Never Smoked  
   <20 pack-years 
   ≥20 pack-years 
 
323(91.5) 
19(5.4) 
11(3.1) 
 
185(52.4) 
77(21.8) 
91(25.8) 
Alcohol Intake1 
   Never 
   <7 drinks per week 
   ≥7 drinks per week 
 
98(27.8) 
191(54.1) 
64(18.1) 
 
124(35.1) 
143(40.5) 
86(24.4) 
Diabetes1 
   No 
   Yes 
 
340(96.3) 
13(3.7) 
 
316(89.5) 
37(10.5) 
 
                                                 
1 P<0.05 
2 Pennsylvania, Ohio, West Virginia 
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A stratified univariate analysis by state residency was attempted based on t he 
difference seen between the geographic distribution of cases and controls (cases 
outside of the Pennsylvania, Ohio, West Virginia vicinity: n=154(44%); OR=8.24, 
95%CI=4.98-13.62). This was not possible due to the non-convergence of maximum 
likelihood estimates in several of the attempted regression models. In order to adjust for 
the difference in geographic residency, this covariate was included in all of the 
multivariate models. 
 
2.3.2 Medical History 
Family members with a history of cancer were found to be significant in the univariate 
analysis and t his increased with increasing family members (1 family member 
OR=1.586, 95%CI=1.113-2.260, 2-3 members OR=2.066, 95%CI=1.350-3.161). The 
one-family member significance held up i n two of our models but a t rend could no 
longer be seen and it lost significance after adjusting for industry and occupation.  
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Table 2-2 Multivariate Analysis of Medical History and Cancer 
Variable Cases 
(n=353) 
Controls(n=353) cOR 95%CI aOR3 95%CI aOR4 95%CI aOR5 95%CI 
Asthma 
     Never  
     Ever 
 
319(90.4) 
34(9.6) 
 
312(88.4) 
41(11.6) 
 
1.0 
0.82 
 
0.51-
1.31 
      
Hay Fever 
     Never 
     Ever 
 
285(80.7) 
68(19.3) 
 
320(90.7) 
33(9.3) 
 
1.0 
2.52 
 
1.56-
4.09 
 
1.0 
2.18 
 
1.08-
4.37 
 
1.0 
2.47 
 
1.19-
5.11 
 
1.0 
4.40 
 
1.46-
13.26 
Eczema 
     Never 
     Ever 
 
332(94.1) 
21(5.9) 
 
341(96.6) 
12(3.4) 
 
1.0 
1.75 
 
0.86-
3.56 
      
Immunologic 
Disease 
     Never 
     Ever 
 
 
341(96.6) 
12(3.4) 
 
 
345(97.7) 
8(2.3) 
 
 
1.0 
1.5 
 
 
0.61-
3.67 
      
Epilepsy 
     Never 
     Ever 
 
349(98.9) 
4(1.1) 
 
350(99.2) 
3(0.8) 
 
1.0 
1.33 
 
0.30-
5.96 
      
Cancer 
     Never 
     Ever 
 
322(91.2) 
31(8.8) 
 
327(92.6) 
26(7.4) 
 
1.0 
1.21 
 
0.70-
2.08 
      
Family 
History of 
Cancer 
     None 
    1 Relative 
2-3Relatives 
 
 
 
109(30.9) 
153(43.3) 
91(25.8) 
 
 
 
151(42.8) 
138(39.1) 
64(18.1) 
 
 
 
1.0 
1.59 
2.07 
 
 
 
1.11-
2.26 
1.35-
3.16 
 
 
 
1.0 
1.73 
1.52 
 
 
 
1.00-
2.97 
0.83-
2.81 
 
 
 
1.0 
1.82 
1.56 
 
 
 
1.04-
3.18 
0.84-
2.92 
 
 
 
1.0 
1.89 
1.84 
 
 
 
 
0.86-
4.57 
0.73-
4.64 
 
                                                 
3 Model adjusted for education, race, smoking, alcohol, diabetes, residency 
4 Model adjusted for education, race, smoking, alcohol, diabetes, residency, chemical exposure, loud noise 
exposure, family history of cancer, hay fever 
5 Model adjusted for education, race, smoking, alcohol, diabetes, residency,  chemical exposure, loud noise 
exposure, family history of cancer, hay fever, dental x-rays, industry(professional, finance, transportation, 
manufacturing), occupation(managerial/professional, service, operators/fabricators/laborers), military service 
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All of our multivariate models showed a s ignificant increased association with 
acoustic neuroma in people who have a history of hay fever (aOR=4.40, 95%CI=1.46-
13.26) and this relationship existed after adjusting for education, race, smoking, alcohol, 
diabetes, residency, chemical exposure, loud noise exposure, family history of cancer, 
dental x-rays, industry(professional, finance, transportation, manufacturing), occupation 
(managerial/professional, service, operators/fabricators/laborers), and military service. 
Other medical history such as asthma, eczema, immunologic disease, epilepsy, or 
cancer did not reach significance (Table 2-2). 
2.3.3 Environmental Exposures 
Environmental exposures showed that there were more controls exposed to 
occupational noise and chemicals than acoustic neuroma cases (OR=0.417, 
95%CI=0.298-0.585, OR=0.683, 95%CI=0.503-0.928 respectively). These factors were 
not found to be significant after adjusting for socio-demographic factors such as 
education, race, smoking, alcohol, diabetes, and residency. There was no s ignificant 
difference in recreational loud noise hobbies. 
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Table 2-3 Multivariate Analysis of Environmental and Occupational Exposures 
Variable Cases 
(n=353) 
Controls 
(n=353) 
cOR 95%CI aOR6  95%CI aOR7 95%CI aOR8 95%CI 
Loud 
Hobbies9 
   Never 
   Ever  
 
 
94(26.6) 
259(73.4) 
 
 
87(24.6) 
266(75.4) 
 
 
1.0 
0.88 
 
 
0.61-
1.28 
      
Loud 
Occupational 
Noise 
   Never 
   Ever 
 
 
 
218(61.8) 
135(38.2) 
 
 
 
151(42.8) 
202(57.2) 
 
 
 
1.0 
0.42 
 
 
 
0.30-
0.59 
 
 
 
1.0 
0.68 
 
 
 
0.37-
1.26 
    
Occupational 
Chemical 
Exposure10 
     Never 
     Ever 
 
 
 
184(52.1) 
169(47.9) 
 
 
 
152(43.1 
201(56.9) 
 
 
 
1.0 
0.68 
 
 
 
0.50-
0.93 
 
 
 
1.0 
0.85 
 
 
 
0.54-
1.35 
    
Tobacco 
Pack-years 
 
   Never 
Smoked  
   <20 pack-
years 
   ≥20 pack-
years 
 
 
 
323(91.5) 
 
19(5.4) 
 
11(3.1) 
 
 
 
185(52.4) 
 
77(21.8) 
 
91(25.8) 
 
 
 
1.00 
 
0.16 
 
0.05 
 
 
 
 
 
0.09-
0.30 
0.02-
0.13 
 
 
 
 
 
0.14 
 
0.05 
 
 
 
 
 
0.07-
0.29 
0.02-
0.15 
 
 
 
 
 
0.16 
 
0.06 
 
 
 
 
 
0.07-
0.34 
0.02-
0.18 
 
 
 
 
 
0.11 
 
0.02 
 
 
 
 
 
0.04-
0.30 
0.01-
0.12 
 
 
                                                 
6 Model adjusted for education, race, smoking, alcohol, diabetes, residency 
7 Model adjusted for education, race, smoking, alcohol, diabetes, residency, chemical exposure, loud noise 
exposure, family history of cancer, hay fever 
8 Model adjusted for education, race, smoking, alcohol, diabetes, residency,  chemical exposure, loud noise 
exposure, family history of cancer, hay fever, dental x-rays,  industry(professional, finance, transportation, 
manufacturing), occupation(managerial/professional, service, operators/fabricators/laborers), military service 
9 Target shooting/Hunting, Motorcycle/ATV/Race car, Concert Attendance, Musical instrument, Machine shop, 
Gardening/lawn maintenance with power tools 
10 Tetrachloroethylene, petroleum products, vinyl chloride and chlorinated hydrocarbons, 
inks/dyes/paints/resins/solvents, pesticides/herbicides/fungicides, heavy metals/welding fumes 
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Further analysis was performed on tobacco use and adjusted regression models 
were created. Pack years <20 and ≥20 were compared to never smoked and a 
protective trend was seen that was still present after adjusting for all other significant 
factors (education, race, alcohol, diabetes, residency,  chemical exposure, loud noise 
exposure, family history of cancer, hay fever, dental x-rays, industry(professional, 
finance, transportation, manufacturing), occupation(managerial/professional, service, 
operators/fabricators/laborers), military service). The association is: (<20 pack years 
OR=0.11, 95%CI=0.04-0.30; ≥20 pack years OR=0.02 95%CI=0.01-0.12) (Table 2-3). 
To evaluate this for a potentially strong socio-demographic bias a post-hoc analysis was 
performed by stratifying smoking by education level (<13 years vs. ≥13 years) and 
tobacco remained statistically significant (chi-square p<0.0001). 
2.3.4 Industry 
There was a s ignificantly higher association among cases who worked in the 
professional and finance industries and conversely among controls who worked in the 
transportation and manufacturing industries in the univariate analysis (OR=1.48, 
95%CI=1.029-2.155; OR=2.46, 95%CI=1.218-4.984; OR=0.54, 95%CI=0.307-0.969; 
OR=0.50, 95%CI=0.263-0.950, respectively). These associations were not significant 
after adjusting for education, race, smoking, alcohol, diabetes, and residency. 
Manufacturing was no longer significant after adjusting for education, race, smoking, 
alcohol, diabetes, residency, chemical exposure, and loud noise exposure. 
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Table 2-4 Multivariate Analysis of Industry and Occupation 
Variable Case 
(n=353) 
Control 
(n=353) 
cOR 95% 
CI 
aOR11 95%CI aOR12 95%CI aOR13 95%CI 
Employed  
Not Employed 
246(69.7) 
107(30.3) 
236(66.9) 
117(33.1) 
1.0 
0.87 
0.62-
1.21 
      
 
Usual Industry 
Case 
(n=330) 
Control 
(n=304) 
        
   Professional 
     No 
     Yes  
 
203(61.5) 
127(38.5) 
 
208(68.4) 
96(31.6) 
 
1.0 
1.49 
 
1.03-
2.16 
 
1.0 
1.27 
 
0.67-
2.41 
    
   Business 
     No  
     Yes  
 
305(92.4) 
25(7.6) 
 
286(94.1) 
18(5.9) 
 
1.0 
1.29 
 
0.69-
2.44 
      
   Finance 
     No 
     Yes  
 
297(90) 
33(10) 
 
291(95.7) 
13(4.3) 
 
1.0 
2.46 
 
1.22-
4.98 
 
1.0 
2.42 
 
0.85-
6.91 
    
   Trade 
     No 
     Yes    
 
303(91.8) 
27(8.2) 
 
277(91.1) 
27(8.9) 
 
1.0 
0.84 
 
0.47-
1.50 
      
Transportation 
     No 
     Yes  
 
307(93) 
23(7) 
 
267(87.8) 
37(12.2) 
 
1.0 
0.55 
 
0.31-
0.97 
 
1.0 
1.16 
 
0.44-
3.06 
    
Manufacturing 
     No 
     Yes  
 
309(93.6) 
21(6.4) 
 
270(88.8) 
34(11.2) 
 
1.0 
0.50 
 
0.26-
0.95 
 
1.0 
0.32 
 
0.10-
0.97 
 
1.0 
0.32 
 
0.10-
1.03 
  
   Other 
     No 
     Yes  
 
281(85.2) 
49(14.8) 
 
256(84.2) 
48(15.8) 
 
1.0 
0.91 
 
0.55-
1.49 
      
 
 
 
                                                 
11 Model adjusted for education, race, smoking, alcohol, diabetes, residency 
12 Model adjusted for education, race, smoking, alcohol, diabetes, residency,  chemical exposure, loud noise 
exposure 
13 Model adjusted for education, race, smoking, alcohol, diabetes, residency,  chemical exposure, loud noise 
exposure, family history of cancer, hay fever, dental x-rays,  industry(professional, finance, transportation, 
manufacturing), occupation(managerial/professional, service, operators/fabricators/laborers), military service 
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Usual Occupation Cases(n=339) Controls(n=331) cOR 95% 
CI 
aOR11 95%CI aOR12 95%CI aOR13 95%CI 
Managerial/ 
Professional 
     No 
     Yes  
 
 
155(45.7) 
184(54.3) 
 
 
240(72.5) 
91(27.5) 
 
 
1.0 
3.49 
 
 
2.39-
5.08 
 
 
1.0 
3.51 
 
 
1.85-
6.68 
 
 
1.0 
3.56 
 
 
1.82-
6.94 
 
 
1.0 
3.83 
 
 
1.45-
10.14 
Technical/Sales/ 
Support 
     No 
     Yes  
 
 
273(80.5) 
66(19.5) 
 
 
246(74.3) 
85(25.7) 
 
 
1.0 
0.73 
 
 
0.51-
1.05 
      
Service  
     No 
     Yes  
 
321(94.7) 
18(5.3) 
 
293(88.5) 
38(11.5) 
 
1.0 
0.44 
 
0.24-
0.81 
 
1.0 
0.55 
 
0.24-
1.26 
    
Precision Production/ 
Craft 
     No  
     Yes  
 
 
318(93.8) 
21(6.2) 
 
 
310(93.7) 
21(6.3) 
 
 
1.0 
0.93 
 
 
0.45-
1.93 
      
Operators/Fabricators/ 
Laborers 
     No  
     Yes  
 
 
325(95.9) 
14(4.1) 
 
 
274(82.8) 
57(17.2) 
 
 
1.0 
0.19 
 
 
0.10-
0.38 
 
 
1.0 
0.41 
 
 
0.15-
1.10 
    
Variable Case(n=352) Control (n=353)         
Military service 
    Never 
    Ever 
 
294(83.5) 
58(16.5) 
 
264(74.8) 
89(25.2) 
 
1.0 
0.47 
 
0.30-
0.75 
 
1.0 
0.60 
 
0.30-
1.21 
    
 
2.3.5 Occupation 
Univariate and multivariate analysis of occupational history showed that 
managerial/professional occupations were associated with cases (adjusted OR=3.83, 
95%CI=1.45-10.14). Service occupations and operators/fabricators/laborers were 
associated with controls but none of these maintained significance in multivariate 
analysis. Multivariate models for occupation were adjusted for education, race, smoking, 
alcohol, diabetes, residency, chemical exposure, loud noise exposure, family history of 
cancer, hay fever, dental x-rays, industry(professional, finance, transportation, 
manufacturing), occupation(managerial/professional, service, 
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operators/fabricators/laborers), military service. History of military service was not 
significant after adjusting for education, race, smoking, alcohol, and diabetes (OR=0.53, 
95%CI=0.283-1.015) (Table 2-4). 
2.4 DISCUSSION 
Significant associations have been fairly well established between ionizing radiation 
exposure and l ong-term risk of developing central nervous system neoplasm. These 
exposures include large nuclear events like the atomic bomb2,3 and radiation treatments 
to the head and neck. 4-6The only known hereditary risk is neurofibromatosis type 2. 
This causes damage to the tumor suppressing protein neurofibromin which allows 
proliferation of tumor cells in nervous system tissue. 
2.4.1 Generalizability 
Acoustic neuromas are benign yet potentially debilitating tumors. This generally slower 
growth pattern gives patients the ability and the motivation to seek out the most 
appropriate and high quality care. This often involves extensive research on behalf of 
the patient, who seeks to understand all available treatment modalities. This search 
frequently involves travel to a s pecialized center of care. Due to the relative rarity of 
these tumors, acoustic neuroma experts tend to be concentrated in large academic 
institutions and patients often need to travel significant distances from their home in 
order to receive appropriate care.  
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Based on an average incidence rate of 1 per 100,000 person-years and the 2000 
USA census (total population 281,421,908 [www.census.gov]), we would estimate that 
2,800 new acoustic neuroma cases were diagnosed in the USA every year within our 
study period. The University of Pittsburgh has performed Gamma knife Stereotactic 
Radiosurgery in approximately 100 ac oustic neuroma patients per year for the past 
several years. This represents treatment of roughly 3-4% of all American cases of 
acoustic neuroma every year. Since approximately half of our patients (46%) are from 
Pennsylvania, this also represents the treatment of about 37% of the local acoustic 
neuroma cases in this department with Gamma Knife Radiosurgery (12,300,000 people 
living in Pennsylvania=1230 new cases to have been diagnosed over the ten year 
period between 1997-2007). 
2.4.2 Limitations and Socioeconomic Differences 
Choosing a hospital based control population can present several challenges. Although 
our case population is largely representative of North American acoustic neuromas, 
there is still a large proportion of our patients who have the means to travel for their care 
(out of state patients=44%) while the control group is a mostly local population (out of 
state controls=9%). In this study we can clearly see that there are some discrepancies 
between cases and controls with regards to geographic location, education, and 
occupation. We see that most of the univariate differences no longer exist after 
adjusting for socio-demographic factors in our analysis.  
This being said, the strong association between cases and 
managerial/professional occupations (adjusted OR=3.83, 95%CI=1.45-10.14) 
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contrasted with a greater proportion of controls in the manual labor occupations and the 
manufacturing industry probably indicates a potential discrepancy in healthcare access 
and delivery. In the setting of a s low-growing tumor that can only be di agnosed via 
costly imaging tests such as a computed tomography or magnetic resonance imaging of 
the brain, discrepancies in healthcare access and diagnostic delay are likely to be seen. 
This type of significant difference has been seen in a previous study by Inskip P, et al 
(2003)28when looking at education and family income. It showed that there was an 
association between increasing family income, college education and acoustic neuroma 
(4 year college/graduate school OR=3.4/3.2, 95%CI=1.7-6.6/1.5-6.7; household income 
>75,000/year: OR=7.2, 95%CI=2.5-20; family income P-trend <0.001).  
Unfortunately a more detailed analysis of race is not possible in this study due to 
the small amount of non-white acoustic neuroma cases. Interestingly, though, an ad-hoc 
look at our data revealed that 5 out of the 8 non-white cases had a 
managerial/professional occupation. This gives more weight to the argument that 
acoustic neuroma diagnosis is more likely associated with better healthcare access and 
socioeconomic status than race. 
2.4.3 Acoustic Trauma 
Loud noise has been found to be associated with acoustic neuroma in previous studies. 
These were all case-control designed studies that looked at occupational or recreational 
exposure to loud noise (Preston-Martin, et.al. (1989): occupational noise OR=2.2; C G 
Edwards, et al (2005): occupational/recreational noise OR=1.55; B Schlehofer, et al 
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(2007): occupational noise OR=2.31; M Hours, et al (2009) occupational/recreational 
noise OR=2.55). These were all interview and questionnaire based studies.  
It is very difficult to validate exposures to loud noise and there is always the 
possibility of recall bias. A further study by C G Edwards, et al (2007)25attempted to look 
at noise in an objective way by taking noise exposure data from an occupational census 
in Sweden. This study found no significant association with loud noise exposure. Our 
data show that there was more occupational loud noise exposure and chemical 
exposure among controls but this was most likely just an ar tifact of the occupational 
differences and did not persist in multivariate analysis. 
2.4.4 Atopic Disease 
Studies have found significant acoustic neuroma associations with allergies and 
immunological disease. Brenner A, et al (2002)19found a positive association with hay 
fever, food allergy, and ot her allergies (OR=2.36, 95%CI=1.38-4.03; OR=3.01 
95%CI=1.06-8.53; OR=3.81 95%CI=1.45-9.99; respectively). Schlehofer B, et al 
(2007)20found a positive association with hay fever (OR=2.20 95%CI=1.09-4.45). The 
biological plausibility is not very well developed or understood. There is evidence 
described by Neiters A, et al (2004).21that an association exists with polymorphisms in 
T-helper cell type1, T-helper cell type2, and cytokine genes related to hay fever and 
atopic disease and this chronic immune cell activation may be related to malignancies. 
Brenner A, et al (2002)19suggested that this may in fact be the result of a diagnostic 
bias. She argues that if allergic rhinitis contributes to Eustachian tube dysfunction and 
otitis media, a more thorough work up might ensue; resulting in the incidental diagnosis 
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of acoustic neuroma. Our study found a strong and significant association with hay fever 
that persisted in multivariate analysis (aOR=3.91, 95%CI=1.35-11.30). 
2.4.5 Tobacco 
Tobacco was seen to have a protective effect against acoustic neuroma in this study. 
The biologic plausibility of this effect is unclear but the protective effect of tobacco 
against acoustic neuroma has been reported in two previous publications. One 
prospective study of 1.2 million women in the United Kingdom found that there is a 
decreased risk among current smokers (Relative Risk=0.41, 95%CI=0.24-0.70, 
P=0.001) of developing acoustic neuroma.22A different case-control study in the UK and 
Nordic countries found that acoustic neuroma associated risk was significantly lower in 
current smokers who regularly smoked cigarettes (OR= 0.7, 95%CI=0.6-0.9).23A 
protective effect of tobacco on other brain tumors has not been seen. 22,23,29It has been 
well established in the literature that smoking has shown a protective effect against 
Parkinson’s Disease but the mechanism for this is poorly understood and most of the 
evidence points towards nicotine’s dopaminergic and neuroprotective effects.30  
Schoemaker, MJ (2007)23and Benson, VS (2010)22put forth a hypothesis that the anti-
estrogenic effect of tobacco31may be pr otective against acoustic neuroma. (This idea 
was developed because hormone-replacement therapy was found to be an elevated 
risk in acoustic neuroma development in another prospective study (Relative Risk=1.58 
95%CI=1.02-2.45)).32Other hypotheses include a potential tumor suppression effect by 
tobacco or perhaps a diagnostic bias effect from people attributing symptoms such as 
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imbalance and hearing loss to smoking rather than pursuing diagnostic tests to rule out 
a brain tumor. 
2.4.6 Low Dose Radiation 
Our previously reported analysis of low dose radiation exposure that was part of our 
case-control study showed that frequent exposure to dental x-rays at least once every 
2-5 years (adjusted OR=2.28, 95% CI= 1.16-4.48) and once a year (adjusted OR=2.01, 
95% CI=1.01-3.98) compared to those less than once every five years is associated 
with acoustic neuroma. This association was present in multivariate models adjusted for 
socio-demographic factors, medical history, and occupational history. No significant 
association was found with cellular phone use and acoustic neuroma. 16 
2.5 CONCLUSIONS 
Acoustic neuromas remain a relatively rare tumor with a poorly understood etiology and 
risk factors. Although prospective cohort studies are the ideal standard for establishing 
risk, a case-control design remains an appropriate method for studying this rare tumor 
with an incidence rate of about 1:100,000 person-years. Better healthcare access likely 
plays a r ole in the diagnosis of this tumor. Hay fever is strongly associated with an 
increase risk of acoustic neuromas. Acoustic noise trauma was not found to be 
associated with acoustic neuroma but this exposure requires more objective and 
validated measures in order to further investigate this as a potential risk factor. Tobacco 
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use demonstrates a protective effect against acoustic neuroma development but this 
mechanism is poorly understood and tobacco remains a public health problem and a 
significant risk factor for much more common malignancies. 
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3.0  HEALTH-RELATED QUALITY OF LIFE OUTCOMES AFTER GAMMA KNIFE 
RADIOSURGERY FOR ACOUSTIC NEUROMA: A COMPARISON TO THE NORMAL 
POPULATION 
3.1 INTRODUCTION 
Relatively few published studies are available to define the  l ong term health related 
quality of life of  patients who undergo one or more management  options for acoustic 
neuroma, also known as vestibular schwannoma.33-35Most such studies have compared 
outcomes after one or more various treatment modalities but fail to compare 
management outcomes to general population norms. Quality of life outcomes are 
increasingly important to acoustic neuroma patients given their choice of treatment 
options and t he recognition of a t umor at earlier stages. Early recognition has been 
facilitated by the widespread use of magnetic resonance imaging (MRI) for patients with 
symptoms of imbalance or hearing dysfunction. Using a newly developed survey 
methodology and the Short-Form 36 Item Health Survey (SF-36),36the present report 
evaluates the long term outcomes of acoustic neuroma patients who underwent Gamma 
Knife ® radiosurgery and compares these outcomes to published outcome data in the 
US normal population.  
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3.2 METHODS 
3.2.1 Survey Design 
As part of a comprehensive study of both risk factors for development of an acoustic 
neuroma as well as long term outcomes, we developed a s urvey instrument that 
covered potential etiological factors as well as comprehensive outcome data. This study 
received the approval of the University of Pittsburgh Institutional Review Board for 
Human Research and informed consent was obtained from all study participants.  
3.2.2 Patient Recruitment  
Patients were recruited from the University of Pittsburgh Gamma Knife Radiosurgery 
database, which included 1475 patients who underwent Gamma Knife stereotactic 
radiosurgery (SRS) at the University of Pittsburgh Medical Center for a new or recurrent 
acoustic neuroma in the interval between August, 1987 and December 31, 2010. In 
order to maximize potential follow up i n patients who underwent SRS since the 
integration of the MRI for treatment planning, we selected patients who underwent SRS 
between the years 1997-2007. The patients were given the Acoustic Neuroma survey 
questionnaire and a Short Form 36-Item Health Survey v2.0 (SF-36). All patients were 
contacted by written letter via the United States postal service. A questionnaire was 
mailed along with a pre-paid return envelope. Patients were given the option to fill out 
the questionnaire by hand or have it done over the telephone with a trained recruiter or 
to send it via email. The majority of patients opted to complete their questionnaire via 
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postal service (339, 96%), ten patients via email (3%) and four via telephone interview 
(1%).  
Eight hundred and twenty two acoustic neuroma patients were treated with 
(SRS) between 1997-2007. A total of 420(51%) patients consented to the survey and 
ultimately 353 (43%) patients completed the necessary components to be included in 
this final analysis. Two patients had missing data and did not complete the SF-36 
portion of the questionnaire. The Mean age of the participants was 60(standard 
deviation ±12) years old at the time of the SF-36 questionnaire. Mean age at diagnosis 
of the acoustic neuroma was 53 years (standard deviation ±12). Median interval from 
date of diagnosis to (SRS) was 3 months (range 0-265), median time from (SRS) to this 
study was 63 months (range 18-141). Average tumor volume was 0.5cm3 (range 0.012-
17.3) and median radiation dose to the tumor margins was 13Gy (range 7-30). Thirty 
(8.5%) patients had undergone a pr ior surgical resection before SRS. Three (0.9%) 
patients had undergone prior fractionated radiation therapy before SRS. 
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Table 3-1 Demographics and Tumor Descriptives 
 
3.2.3 Questionnaire 
A functional outcomes questionnaire was developed. The survey assessed the patient’s 
perception of their current hearing status in both the tumor and the non-tumor ear, 
tinnitus, balance disorder symptoms, and vertigo. Patients were also queried over their 
overall satisfaction with the procedure and if they would recommend the procedure to 
somebody else. We also administered the SF-36 in order to further assess health 
related quality of life.  
Acoustic Neuromas Treated between 1997-2007 822 
Patients In Study 353 (43%) 
Median Tumor Volume 0.5cm3 (range 0.012-17.3) 
Median Dose of Radiation to Tumor Margin 13 Gy (range 7-30) 
Gender  
   Men 
   Women  
 
175 (49.6%) 
178 (50.4%) 
Mean Current Age (Standard Deviation) 60 (12) 
Mean Age Of Case At Diagnosis (SD) 53 (12) 
Tumor Location  
   Right 
   Left 
 
175 (49.6%) 
178 (50.4%) 
Previous Craniotomy 30 (8.5%) 
Previous Radiation Treatment 3 (0.9%) 
Median Time From Diagnosis to Treatment (Months) 3 (0-265) 
Median Time From Treatment To Questionnaire (Months) 63 (18-141) 
Surgery For Tumor Progression 
   Repeat Gamma Knife 
   Microsurgery 
 
2 
1 
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3.2.4 Statistical Analysis 
Descriptive statistics were used to display demographic data. Medians, Means, 
standard deviations, and overall proportions were used when appropriate. Pearson’s 
Correlation Coefficient, student’s t-tests, and ANOVA were used where appropriate in 
order to explore relationships between variables. All data were analyzed using PASW 
Statistics 18, Release Version 18.0.0 (© SPSS, Inc., 2009, Chicago, 
IL, www.spss.com) 
3.2.5 SF-36 Analysis 
SF-36 questionnaire data were analyzed according to the SF-36v2 user’s 
manual37scoring criteria. Summary scores for physical and m ental health (PCS and 
MCS respectively) were also obtained according to the scoring criteria for ease of 
interpretation and overall comparison. Normalized t-scores were obtained for each of 
the eight scales as well as the summary scores. The data were normalized to the 1998 
SF-36 US population norms as outlined in the user’s manual. This normalized data are 
presented for a more meaningful interpretation of the data. It allows for easy 
comparison to US population norms and facilitates comparisons made across 
subgroups. It also eliminates excess variability of standard deviations and equates the 
central tendencies across scales. The US population norms demonstrate a mean of 50 
and a standard deviation of 10 for each of the eight scales as well as the two summary 
scores.37Student’s t-tests were performed on summary scores between the patients 
while stratifying according to functional status in order to determine significant 
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differences in summary scores according to functional status. One-sample t-tests were 
performed between patients and 1998 US population norms in order to determine 
statistically significant differences between mean scores in each of the eight scales and 
the two summary scores as well as a stratified analysis by age grouping. The One-
sample t-tests used the population mean of 50 for test comparisons of overall score and 
the corresponding age group means for the stratified analysis as published by the SF-
36.37  
3.2.6 Effect Size Scoring 
It was determined that a minimal clinically significant difference in SF-36 scores would 
follow Cohen’s formulation of effect size (ES) scoring. This was done by dividing the 
difference in mean scores by the standard deviation of the patient’s score. The general 
accepted ranges were represented as 0.20 to 0.50 for a “small” effect size, 0.50 to 0.80 
for a “ medium” effect size and g reater than 0.80 would be “large”. This usually 
translates to a mean score difference of around 2 to 5 points for a clinically significant 
difference. .38-40Because the 1998 US population norms carry a mean scale score of 50 
and a s tandard deviation of 10, the normalized data can be interpreted as having an 
effect size change of 0.10 for every one point difference in mean score when comparing 
to the population norms.37 
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3.3 RESULTS 
3.3.1 Functional Outcomes 
Two hundred and forty six (70.3%) patients reported that they currently do not  have 
useful hearing in the tumor ear. For our questionnaire, we defined useful hearing as 
being able to use the ear at least fairly in an everyday conversation. Of interest, 334 
(94.9%) patients reported retention usable hearing in the non-tumor ear. Fifteen patients 
(4.2%) described their hearing as either poor or deaf in both ears.  
Tinnitus was reported by 163 ( 41.7%) patients either often or continuously. 
Imbalance symptoms were noted by 121 (34.4%) patients either often or continuously. 
Vertigo symptoms were reported by 42 (12%) patients either often or continuously. 
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Table 3-2 Self-reported Current Functionality 
 n (%) 
Hearing in Tumor Ear (Usable: Excellent/Good/Fair vs. Non-Usable: 
Poor/Deaf) For Use in an Everyday Conversation 
• Usable 
• Non-Usable 
 
 
104 (29.7) 
 
246 (70.3)  
Hearing in Non-Tumor Ear (Usable: Excellent/Good/Fair vs. Non-
Usable: Poor/Deaf) For Use in an Everyday Conversation 
• Usable 
• Non-Usable 
 
 
334 (94.9) 
 
18 (5.1) 
Tinnitus in Tumor Ear 
• Never/Rarely 
• Often/Continuous 
 
190 (53.8) 
 
163 (41.7) 
Tinnitus in Non-Tumor Ear 
• Never/Rarely 
• Often/Continuous 
 
334 (94.6) 
 
19 (5.4) 
Tinnitus in Both Ears 
• Never/Rarely 
• Often/Continuous 
 
314 (89) 
 
39 (11) 
Balance Problems 
• Never/Rarely 
• Often/Continuous 
 
231 (65.6) 
 
121 (34.4) 
Vertigo or Dizziness 
• Never/Rarely 
• Often/Continuous 
 
308 (88) 
 
42 (12) 
Are You Satisfied With Your Current Overall Functionality and Activity 
Level? 
• Yes 
• No  
 
 
318 (91.1) 
 
31 (8.9) 
Would You Recommend The Gamma Knife Radiosurgery Procedure 
for a Friend or Family Member With Your Type of Tumor? 
• Yes 
• No  
 
 
337 (96.8) 
 
11 (3.2) 
Additional surgeries 
• Repeat Gamma Knife Radiosurgery 
• Unspecified in Self-Report 
 
2(0.6) 
 
5(1.4) 
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3.3.2 Overall Satisfaction 
Three hundred eighteen patients (91.1%) reported that they were satisfied with their 
current level of functioning and 337 (96.8%) noted that they would recommend the 
Gamma Knife Radiosurgery procedure to a friend or relative if they were to develop an 
acoustic neuroma (Table 3-2). 
3.3.3 SF-36 Outcomes 
The SF-36 scores were compared to 1998 US population norms. Our patients reported 
outcomes that either matched or exceeded outcomes noted for 1998 US population 
norms. The vitality category was both statistically and clinically significant with a “small” 
effect size of 0.29 (p<0.0001).Body pain, social functioning, and m ental health 
categories were statistically better than the population norms (p<0.0001, p=0.008, 
p=0.009 respectively) but they did not meet a clinically significant effect size of at least 
0.2 (Table 3-3). The Mental Health Summary Score was significantly higher than 
population norms (mean score difference 1.72, p=0.001) but again, it was not clinically 
significant. 
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Table 3-3 Effect Size 
 
Sf-36 Scale 
Case/US Population 
Effect Size 
Physical Functioning 0.03 
Role Physical  0.05 
Body Pain 0.1814 
General Health 0.10 
Vitality 0.2915 
Social Functioning 0.1314 
Role Emotional 0.06 
Mental Health 0.1314 
                                                 
14 Statistically significant at p<0.05 according to one-sample t-test comparing to a mean of 50  
15 Both statistically and clinically significant 
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Figure 3-1 Normalized SF-36 Scores For Patients With 95%CI. Scores Represent The Eight 
Domains Measured And Are Compared To A Normalized Mean Of 50 
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Figure 3-2 Normalized SF-36 Scores For Patients With 95%CI. Scores Represent The 
Overall Physical And Mental Summary Compared To A Normalized Mean Of 50 
 
 
 
 
Summary scores were not significantly different between men and women (mean 
difference of PCS 0.82 p=0.43, MCS 1.55 p=0.14) in our cohort. We found a significant 
difference in PCS mean scores stratified by age groupings that showed them lowering 
with age (ANOVA p<0.0001) but no significant difference was found in MCS age groups 
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(ANOVA p=0.37). The SF-36 US population norms for PCS and M CS were also 
published as stratified by age groupings37and these were compared to our patient’s age 
groups. Our patients did the same or better than US norms in all age groups. Our 
patients had statistically significant better scores than US norms in the following age 
groups: 25-34 MCS=52.46  p=0.027, 45-54 PCS=53.30  p =0.001, 55-64 PCS=52.08  
p<0.0001, 65-74 PCS=47.45 p<0.021, 75+ PCS=45.04  p=0.001. 
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Figure 3-3 Normalized SF-36 Scores With 95%CI Stratified By Age Group. Scores 
Represent The Overall Physical And Mental Summary Scores In Each Age Group. The Line Of 
Asterisks [****] In Each Bar Represents The Varying Normalized Mean For Each Age Group For 
Comparison 
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No significant correlation was found between the length of time from treatment 
and the summary scores (Pearson’s correlation coefficient: PCS -0.054 p=0.32, MCS 
0.07 p=0.194). 
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Figure 3-4 Scatter Plot With Best-Fitted Line Demonstrating No Significant Correlation 
Between Time From Follow Up To Physical Component Summary Score (PCS Correlation 
Coefficient -0.054 P=0.32) 
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Figure 3-5 Scatter Plot With Best-Fitted Line Demonstrating No Significant Correlation 
Between Time From Follow Up To Mental Component Summary Score (MCS Correlation 
Coefficient 0.07 P=0.194) 
 
 
 
 
Mean SF-36 summary scores stratified by functional differences demonstrated 
significant differences in hearing, balance, and vertigo. Non-functional hearing in the 
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tumor ear showed a s ignificantly lower PCS (-2.79, effect size -0.27, p=0.014) but no 
significant difference in MCS. Regular imbalance and vertigo problems was significantly 
associated with lower PCS and MCS (imbalance PCS -6.41 ES -0.56; vertigo PCS -9.53 
ES -0.73; imbalance MCS -4.06 ES -0.36; vertigo MCS -7.65 ES -0.71, p<0.0001). No 
significant differences were found for tinnitus. 
 
 
 
Table 3-4 Functional Status Effect on Summary Scores 
 Physical Summary Score Mental Summary Score 
Functional Status Mean 
Difference 
Effect 
Size 
P 
Value 
Mean 
Difference 
Effect 
Size 
P Value 
Hearing In Tumor 
Ear: 
 Non-Functional 
Vs. Functional   
-2.79 -0.2716 0.01 -0.18 -0.02 0.87 
Tinnitus In Tumor 
Ear: 
Continuous/Often 
Vs. Rarely/Never 
-1.87 -0.19 0.10 -0.4 -0.04 0.68 
Imbalance 
Continuous/Often 
Vs. Rarely/Never 
-6.41 -0.5616 <0.001 -4.06 -0.3616 <0.001 
Vertigo 
Continuous/Often 
Vs. Rarely/Never 
-9.53 -0.7316 <0.001 -7.65 -0.7116 <0.001 
 
                                                 
16 Clinically significant effect size 
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3.4 DISCUSSION 
Patients with acoustic neuromas are presented with various management options that 
range from continued observation (wait and s can), microsurgical removal by one of  
several surgical approaches, or stereotactic radiosurgery using one o f several 
methodologies.  Since 1987 we have evaluated the long term role and outcomes of 
Gamma knife radiosurgery in an increasing experience. In our observational cases, we 
have noted that most (>80%) patients demonstrate clinical worsening and i mage 
defined tumor growth within a period of 5- 10 years. Since our experience also confirms 
that hearing preservation is better when patients undergo SRS earlier41-43In order to 
evaluate both potential etiological factors in the development of acoustic neuromas as 
well as to survey long term outcomes, we developed a specially designed survey to 
assess both factors. The present study was designed to define the outcomes of 
acoustic neuroma patients who underwent GK SRS in the second ten year interval of 
our evolving evaluation of SRS using the Leksell Gamma knife (AB Elekta, Stockholm, 
Sweden).  We compared these results to standard population outcome norms using 
data provided by the SF-36 scoring manual. 
Several published studies have evaluated the outcomes  of Gamma Knife 
Radiosurgery and indicate that this management strategy is associated with long term 
improvement in outcomes, especially in comparison to outcomes reported after 
microsurgical management.44-50All such studies have certain limitations. Since there is 
no widely used acoustic neuroma specific questionnaire, there is no uniformity in health 
related quality of life measurement tool. A recent publication by Schaffer, BT. 2010 
showcased what may be t he first attempt at validating an ac oustic neuroma-specific 
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quality of life measurement tool.51Many published studies are underpowered to obtain 
significant results and most of their outcome data were less than four years.  
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Table 3-5 Gamma Knife Radiosurgery Quality of Life Outcomes 
Author  
Follow 
Up 
(Years)  
Quality of Life 
Measurement Tool N Results 
Myrseth E, 
et al 
2005 
1.5-13 GBI17, SF-3618,  168 
 
GK19 fared better than MS20 on 
both measures. Combined SF-36 
scores were lower than Norwegian 
population norms. Stratified GK 
scores were not reported.  
Myrseth E, 
et al 
2009 
2 Sf-36, GBI 88 Prospective look at GK improved 
from baseline on GBI.   
Pollock B, et 
al  
1995 
2-4 Functional outcome 
rating scale 
87 GK Resumed regular activities 
sooner than MS post-op. GK did 
better than MS on functional scale 
but did not reach significance.  
Pollock B, et 
al 
2006 
1-5 HSQ21 82 GK had no prospective decline. MS 
had significant prospective decline.  
Regis J, et 
al 
2002 
3 Functional evaluative 
questionnaire  
210 GK had better functional outcomes 
compared to MS  
Roijen L. 
Van, et al 
1997 
2 “Health and Labor 
Questionnaire” 
(employment 
productivity), SF-36, 
EuroQol 
145 GK had better outcomes than MS. 
GK was more cost-effective than 
MS.  
Sandooram 
D, et al 
2004 
2-5 GBI 165 GK and MS did worse than 
successful observation but 
observed tumors were about half 
the size of treated ones. GK results 
did not reach significance.   
Timmer FC, 
et al 
2009 
0.17-4.6 Sf-36, GBI 97 GK SF-36 results were similar to 
Dutch population norms. GBI did 
not have significant difference.  
 
                                                 
17 Glasgow Benefit Inventory 
18 Short Form-36 Questionnaire 
19 Gamma Knife 
20 Microsurgery 
21 Health Status Questionnaire 
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Our study evaluated 353 acoustic neuroma patients at a median of 5.25 years 
after undergoing radiosurgery. The present study is the first to compare outcomes after 
Gamma Knife Radiosurgery for acoustic neuroma to age matched US population 
norms. A study in the Netherlands also showed that acoustic neuroma patients’ SF-36 
scores were comparable to their Dutch population norms.52A Norwegian study 
compared Norwegian SF-36 population norms to patients who underwent Gamma Knife 
Radiosurgery for an acoustic neuroma.48The Norwegian study looked at combined 
SRS/microsurgery data and did not report stratified SRS scores. These combined 
treatment outcomes showed that patients did the same or slightly worst than their 
country’s population norms. Loyd et al. evaluated outcomes in United Kingdom acoustic 
neuroma patients who underwent a watch and scan strategy and compared them with 
UK SF-36 population norms. His observation cohort did significantly worse than UK 
population norms.53A Dutch cross-sectional study looked at baseline SF-36 scores upon 
initial diagnosis of acoustic neuroma and compared them with Dutch population 
norms.54 These recently diagnosed patients who had not undergone any treatment yet 
also did poorer compared to Dutch population norms.   
The answers to the functional questions that we included in the questionnaire 
have yielded data that on face value could seem to conflict with published data related 
to objective testing such as audiograms in patients eligible for hearing preservation after 
SRS. In the present report 70% of patients reported that they did not have serviceable 
hearing in their tumor side. This series included patients who were deaf or had 
unserviceable hearing at the time of SRS (Gardner Robertson Class III-V) as well as 
patients who had serviceable hearing prior to SRS (Gardner Robertson Class I or II). 
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We have reported that serviceable hearing can be maintained in as many as 70% of 
patients who have serviceable hearing at the time of radiosurgery.55,56The present study 
was a s elf reported outcome study that did not include objective hearing test 
measurements. We did find that patients with non-functional hearing in their tumor ear 
had a significantly lower PCS, but this carried only a small effect size of -0.27 and no 
significant difference was found in the MCS.  
Tinnitus is a commonly reported symptom of patients with acoustic neuromas but 
it is impossible to measure objectively. Patients with acoustic neuromas report that 
tinnitus may be unilateral or bilateral. The impact of tinnitus is variable among patients 
and its presence does not easily correlate with a patient’s level of discomfort.57-59 In this 
study we did not find any significant association between tinnitus and SF-36 summary 
score changes. Our findings agree with previous studies including Loyd et al, 201053,60 
who also failed to find a significant correlation between summary scores and the tinnitus 
handicap index. Other tinnitus studies have shown that approximately 80% of patients 
who suffer from chronic tinnitus did not seek treatment for it.57In this study we found that 
the presence of tinnitus resulted in no consistent impact on activities of daily living. 
Symptoms of a bal ance disorder or vertigo are similarly difficult to measure 
objectively. We also have noted wide variability related to the impact of such symptoms 
among acoustic neuroma patients. Our questionnaire found that our acoustic neuroma 
patients who reported balance or vertigo problems had significantly lower PCS and 
MCS scores of “medium” clinical significance. This finding has been previously shown in 
studies where quality of life impairment was correlated with the presence of imbalance 
or vertigo. 53,60 
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Despite the reported symptoms of hearing loss, tinnitus, and balance disorders, 
91% of our patients report that they were satisfied with their overall level of functioning. 
This high level of satisfaction seems to correlate with their above average performance 
on the SF-36 questionnaire. Unlike our high levels of SF-36 performance in patients 
who underwent Gamma Knife Radiosurgery, Loyd et al. 2010’s53watch and scan cohort 
showed that their physical component and summary scores of the SF-36 were 
significantly lower than the normal population. As described above, they attributed a 
proportion of this to balance symptoms. In addition they were unable to assess the 
impact of hearing dysfunction due to the small number of “observation only” patients 
that actually retained hearing.  
Our patients were found to have similar or better results on their SF-36 summary 
scores compared to the US population and this finding held up even against age-group 
stratification. They are able to maintain their quality of life over the long term as shown 
by the lack of any significant correlation between summary scores and l atency from 
treatment.   
Our well maintained level of health related quality of life is likely attributable to 
several factors. Gamma Knife SRS is a non-invasive management strategy designed to 
obtain tumor control, maintain cranial nerve function, and  avoid the relatively rare but 
significant risks of microsurgical removal. Long term tumor control rates vary from 90 -
98% of patients.42,55,56This contrasts in our experience with the >80% likelihood of tumor 
progression over 10 years if a “wait and scan” approach is adopted. 
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3.5 CONCLUSION 
Overall, patients at an average of five years after undergoing Gamma Knife 
Radiosurgery for an acoustic neuroma reported retention of a high quality of life that 
matches or exceeds quality of life of US population norms. Such patients tend to report 
that they are satisfied with their current of function and  w ould recommend Gamma 
Knife Radiosurgery to a family member or a friend if they were to develop an acoustic 
neuroma.  A lthough symptomatic hearing loss and balance or vertiginous disorders 
were reported to impact negatively on q uality of life, the effect is only of “small” or 
“medium” clinical significance in comparison to US population norms. 
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4.0  DO ACOUSTIC NEUROMAS AFFECT HEARING IN THE NON-TUMOR EAR? 
A CROSS-SECTIONAL LOOK AT THE NON-TUMOR EAR OF PATIENTS 
UNDERGOING GAMMA KNIFE RADIOSURGERY FOR ACOUSTIC NEUROMA AND 
COMPARISON TO NHANES POPULATION NORMS 
4.1 INTRODUCTION 
Many patients with an acoustic neuroma will eventually lose their hearing in the affected 
ear regardless of intervention or even tumor growth.43,61-63This makes hearing in the 
unaffected ear a significant concern for the morbidity of the patient. Acoustic neuromas 
are known to cause unilateral hearing loss that can be demonstrated with elevated 
audiogram thresholds and low speech discrimination scores.  
There is not much published research about the status of a patient’s hearing in 
the non-tumor ear. This study collected audiogram information on 321 acoustic 
neuroma cases in order to describe hearing in the non-tumor ear of patients with 
vestibular schwannoma. We also compared our findings to sample data that are 
generalized to the US population from the National Health and Nutrition Examination 
Survey (NHANES). The goal of this study is to provide a description of hearing in the 
non-tumor ear of patients with acoustic neuroma.   
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4.2 METHODS 
4.2.1 Survey Design 
We developed a survey instrument as part of a comprehensive study which included the 
assessment of risk factors for development of vestibular schwannoma. This 
questionnaire collected potential etiological factors and included noise exposures such 
as occupational noise, loud hobbies, military history, and the use of hearing protection. 
This study received the approval of the University of Pittsburgh Institutional Review 
Board for Human Research and informed consent was obtained from all study 
participants.  
4.2.2 Patient Recruitment 
Patients were recruited from the University of Pittsburgh Gamma Knife Radiosurgery 
database. In the database there are 1475 patients who underwent Gamma Knife 
stereotactic radiosurgery (SRS) at the University of Pittsburgh Medical Center for a new 
or recurrent acoustic neuroma in the interval between August, 1987 and December 31, 
2010. We selected patients who underwent SRS between the years 1997-2007. The 
patients were given our newly developed Acoustic Neuroma questionnaire. All patients 
were contacted by written letter via the United States postal service. A questionnaire 
was mailed along with a pre-paid return envelope. Patients had the option of filling out 
the questionnaire by hand or they could request an interview over the telephone with a 
trained recruiter or they had the option to complete it via email. The majority of patients 
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opted to complete their questionnaire via postal service (339, 96%), ten patients via 
email (3%) and four via telephone interview (1%).  
A total of 822 acoustic neuroma patients were treated by SRS between 1997-
2007. A total of 420(51%) patients consented to the survey and ul timately 353 (43%) 
patients completed all of the necessary components. A total 321 (90.9% of 353) patients 
had complete audiogram data and were included in the final analysis. Audiograms 
closest to the date of diagnosis were used for this study to best approximate a baseline 
reading of hearing status. Median tumor volume was 0.5cm3 (range 0.012-17.3). The 
Mean age of the participants was 54.72 (standard deviation ±12.46) years old at the 
time of diagnosis. Gender and tumor side were both equally divided (men 166 (51.71%), 
right side tumor 163 (50.78%)). Median interval between date of diagnosis and 
audiogram was 22 day s (-3639 to 3769), median time from diagnosis to this 
questionnaire was 77.07 months (0.43-219.6).  
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Table 4-1 Demographics of Acoustic Neuroma Patients 
Acoustic Neuromas 
Treated between 1997-
2007 
822 
 
 Patients Who Responded 
to Questionnaire 
 
 
353(43% of 822) 
 
Patients With Audiogram 
(Included in Study) 
321 (91% of 353) 
Age 
   Mean  
   Std. Deviation 
 
54.72 
12.46 
 
Gender 
   Male 
   Female 
 
 
166 (51.7%) 
155 (48.3%) 
 
Tumor Location  
   Right 
   Left 
 
 
163 (50.8%) 
158 (49.2%) 
 
Median Time From 
Audiogram to Diagnosis 
(Days)  
 
22 (-3639 to 3769) 
 
Median Time From 
Diagnosis To 
Questionnaire (Months) 
 
77.07 (0.43-219.6) 
 
Median Tumor Volume 
 
0.5cm3 (range 0.012-
17.3) 
 
 
 
 58 
4.2.3 Audiograms 
Audiometry is routinely performed in the assessment and care of patients with acoustic 
neuroma. Although the primary reason for audiogram assessment is generally to 
monitor the hearing status in the tumor ear, audiograms are performed bilaterally. For 
this study we collected data from audiograms that our patients had around the time of 
their diagnosis. A trained research assistant who was not involved in the treatment of 
the patients entered the data. We extracted the results from both ears and r ecorded 
hearing levels in decibels (dB) at 500, 1000, 2000, 3000, 4000, 6000, and 8000 Hertz 
(Hz). We also recorded speech discrimination scores (SD) and pr esentation level in 
(dB). The data were separated into tumor ear and non-tumor ear categories. Our 
analysis was focused on the non-tumor ear. Pure tone averages (PTA) = (mean of 0.5, 
1, and 2 KHz) were obtained to describe the hearing levels of speech. 64,65 
4.2.4 Sensorineural Hearing Loss 
We defined normal hearing as hearing threshold levels under 25 (dB)66Hearing loss that 
is attributed to age or loud noise exposure is best identified in the high tones. In this 
study we will refer to high-tone hearing as hearing levels between 3, 4, and 6 (KHz). 
Moderate sensorineural hearing loss (MSNHL) is considered to be he aring levels 
greater than 25 (dB).67Severe sensorineural hearing loss (SSNHL) is defined as any 
measurement of 3, 4, or 6 (KHz) greater than 65 (dB)68  
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4.2.5 NHANES 
The National Health and Nutrition Examination Survey (NHANES) is an effort to obtain 
health and nutritional data on the US population. This survey has been in place on a 
periodic basis since the 1960’s and on a yearly basis since 1999.69 The goal has been 
to obtain data that are representative of the civilian, non-institutionalized US population. 
69In the 2001-2002 sample that we used in this study, there were 13,156 persons 
selected for the sample, 11,039 of those were interviewed (83.9%), and 10,477 (79.6%) 
were examined with various tests in mobile exam centers. 70A “half-sample” of the total 
sample underwent audiogram examination and data have been released on ( n=2046 
people).69-71  
This dataset was chosen because it is close in time to our patient’s audiograms 
and helps to avoid any possible secular trends. We combined the audiogram data to 
obtain both (PTA) and high tone hearing averages (PTA=0.5, 1, and 2 k Hz; high 
tones=3, 4, and 6 kHz). The NHANES study did not test speech discrimination scores.  
The NHANES data had a range of people ages 20 t o 69 ( mean age 41.91 
(95%CI=41.23-42.59)). We selected our patients who were also in this age range for 
comparison (n=286) and c reated 10 year age groups for frequency matching. The 
NHANES sample as well as our patient sample were evenly distributed by gender 
(NHANES: 893 men (48.8% weighted proportion); Patients: 166 men (51.7%)) (Table 
4-5). 
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4.2.6 Noise Exposure 
Subjective exposures were obtained via self-report questionnaire. Patients were asked 
what proportion of time they had exposure to loud occupational noise (loud occupational 
noise is defined as not being able to have a c onversation at speaking level68). Their 
answers were categorized to occupational noise exposure of <50% time vs. ≥50% time. 
Patients who reported positive exposures to occupational noise were also asked how 
much of the time they used hearing protection and their answers were categorized to 
hearing protection use <50% time vs. ≥50% time. Patients were asked if they had ever 
served in the military. Patients were also asked if they had ever participated in loud 
hobbies such as: target shooting/hunting, motorcycle/atv/race car, concert attendance, 
musical instrument, machine shop, gardening/lawn maintenance with power tools and 
how many years they participated in these hobbies. Their answers were categorized to 
<1 year vs. ≥1 to 5 years. 
4.2.7 Statistical Analysis 
Data analysis was performed using SAS version 9.2 (SAS Institute, Cary, North 
Carolina). Descriptive statistics were used to display demographic data. Medians with 
ranges, means with standard deviations, and overall proportions were used when 
appropriate. Medians were compared using the Wilcoxon Mann-Whitney U Test for non-
parametric data when the data did not meet the normality assumption. Univariate 
analysis of categorical data was performed via Pearson’s Chi-Square test. Multiple 
logistic regression was performed in order to obtain the log odds of association between 
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exposures and sensorineural hearing loss. Models were adjusted for age and gender. 
Occupational noise was adjusted for the use of hearing protection.  
In order to account for the complex survey sampling design, NHANES data were 
analyzed using the SURVEYMEANS and S URVEYREG procedures in SAS. 
Appropriate 2 year sample weights were used for the audiogram data as provided by 
the Centers for Disease Control (http://www.cdc.gov/nchs/nhanes/nhanes2001-
2002/AUX_B.htm). Weighted proportions, means, and confidence intervals were 
obtained to describe the NHANES data in order for it to be representative of the US 
population.69-71Hypotheses were tested via F-test of equal means in the SURVEYREG 
procedure.72 
4.3 RESULTS 
4.3.1 Audiograms 
There were 321 audiograms included in this study. Audiogram threshold levels were 
higher in the tumor ear compared to the non-tumor ear across all frequencies and a 
difference is seen in (SD) scores of 26.5% (69.3% vs. 95.8%, respectively).  
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Table 4-2 Mean Audiometric Thresholds (dB) and Speech Discrimination (SD) Scores by 
Affected Ear 
 
 
 
 
4.3.2 Sensorineural Hearing Loss and Loud Noise Exposure (Univariate 
Analysis) 
Mean age was significantly higher among patients with evidence of either (MSNHL) or 
(SSNHL) when compared to normal hearing (+10.8 years and +16.08 years, 
respectively: p<0.0001). Men were in greater proportion for both (MSNHL) and (SSNHL) 
(58.2% and 79.5%, respectively compared to normal hearing 37.1%: p<0.001). Military 
service was greater among (MSNHL) and (SSNHL) (18.7% and 52.3%, respectively 
compared to normal hearing 6.3%: p<0.01). Patients who had evidence of (MSNHL) 
N=321 
Frequency (Hz) 
 
Ear 500 1000 2000 3000 4000 6000 8000 
SD 
(%) 
SD 
Level 
(dB) 
Tumor 
Mean (dB) 
      StDev 
26.35 
18.16 
32.64 
21.79 
40.95 
24.13 
47.95 
24.70 
52.53 
25.08 
55.81 
25.62 
57.39 
27.19 
69.3 
34.70 
63.20 
21.55 
Non-
Tumor 
Mean(dB) 
      StDev 
14.02 
10.62 
14.67 
11.78 
17.65 
14.64 
23.08 
18.06 
28.82 
21.60 
33.07 
22.67 
35.78 
24.92 
95.8 
9.70 
55.94 
20.16 
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and (SSNHL) did not report a greater amount of loud hobbies compared to those with 
normal hearing (p=0.76, p=0.18, respectively).   
 
 
Table 4-3 Univariate and Multivariate Regression Analysis of Loud Noise Exposures and 
Sensorineural Hearing Loss 
Total n=321 
Normal 
Hearing 
n=143(44.55) MSNHL N=134 (41.74) SSNHL N=44 (13.71) 
Variable n(%) n(%) 
p-
value22 aOR23 95%CI 
 
aOR24 
 
95%CI n(%) 
p-
value1 aOR2 95%CI aOR3 95%CI 
Age at Dx 
Mean 
SD 
 
48.31 
10.98 
 
58.39 
10.87 <0.0001 1.11 
1.07-
1.14   
 
64.39 
10.84 <0.0001 1.20 
1.31-
1.28   
Female 
Male 
90(62.9) 
53(37.1) 
56(41.8) 
78(58.2) <0.001 3.59 
2.03-
6.33   
9(20.5) 
35(79.5) <0.0001 17.96 
5.44-
59.37   
Ever served 
in the 
military 
No 
Yes 
134(93.7) 
9(6.3) 
 
109(81.3) 
25(18.7) 
 
 
0.002 
 
 
1.26 
 
0.50-
3.16   
 
 
21(47.7) 
23(52.3) 
 
 
<0.0001 
 
 
1.71 
 
 
0.47-
6.17   
Any loud 
hobby 
<1year 
≥1-5 years 
44(30.8) 
99(69.2) 
39(29.1) 
95(70.9) 0.76 1.01 
0.54-
1.88   
9(20.5) 
35(79.5) 0.18 0.99 
0.32-
3.09   
Occupational 
Loud Noise 
<50%Time 
>=50%TIme 
 
 
127(88.8) 
16(11.2) 
 
112(83.6) 
22(16.4) 0.21 2.34 
1.01-
5.38 
 
 
 
1.68 
 
 
0.73-
3.87 
 
29(65.9) 
15(34.1) <0.001 8.82 
2.31-
33.64 
 
 
 
2.88 
 
 
1.00-
8.28 
              
 
 
                                                 
22 Univariate analysis based on chi-square test 
23 Odds ratio adjusted  for age and gender 
24 Odds ratio of occupational noise adjusted for hearing protection use ≥50% time (hearing protection data was 
only obtained for occupational noise) 
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4.3.3 Univariate Analysis of Occupational Noise Exposure 
A greater proportion of patients who reported occupational loud noise exposure ≥50% of 
the time also had evidence of (MSNHL) and (SSNHL) but this only reached univariate 
significance for (SSNHL). ((MSNHL) 16.42% vs. 11.19% normal hearing: p=0.21, 
(SSNHL) 34.09% vs. 11.19% normal hearing: p<0.001) (Table 4-3).  
Further analysis was performed on occupational noise exposure to look at both 
(PTA) and high tone hearing. Mean age was found to be similar between exposed and 
non-exposed groups (<50% Time; Mean age 55.04 (SD=12.20), >=50% Time; Mean 
age 53.11 (SD=13.72): p=0.30). The audiogram frequencies were averaged into low 
(speaking) tones (0.5, 1, and 2 kHz) and high tones (3, 4, and 6 kHz) and compared by 
occupational noise exposure. The (≥50% time occupational noise) group had a (PTA) 
threshold that was elevated but not significantly (difference 2.2; p=0.89) and a high tone 
threshold that was significantly elevated (difference 9.7; p=0.01). 
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Table 4-4 Audiometry of Pure Tone Average (PTA) and High Tone Thresholds by Noise 
Exposure 
Amount of Occupational Noise Exposure (PTA)25 High Tones26 
<50% Time 
Mean age: 55.04 (SD 
12.20) 
N 268 268 
Mean (SD) 15.09 (10.20) 26.72 (18.43) 
>=50% Time 
Mean age: 53.11 (SD 
13.72) 
N 53 53 
       Mean 
(SD) 
17.26 (15.10) 36.42 (24.30) 
p-value27  0.89 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
25 500, 1000, and 2000 kHz 
26 3000, 4000, and 6000 kHz 
27 Based on Wilcoxon-Mann-Whitney Test 
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4.3.4 Sensorineural Hearing Loss Regression Model 
Multiple logistic regression models were built with the loud noise exposure variables 
adjusted for age, and gender. Age and gender were significant in both moderate and 
severe sensorineural hearing loss (age (MSNHL) Odds Ratio (OR) =1.11; 95%CI 1.07-
1.14; (SSNHL) OR=1.20; 95%CI 1.31-1.28; gender (MSNHL) OR=3.59 95%CI 2.03-
6.33; gender (SSNHL) OR=17.96 95%CI 5.44-59.37). Military service was associated 
with (MSNHL) and (SSNHL) but did not reach significance ((MSNHL) OR=1.26 95%CI 
0.50-3.16; (SSNHL) OR=1.71 95%CI 0.47-6.17). loud hobbies did not show an 
association with (MSNHL) or (SSNHL). Occupational loud noise exposure did show a 
significant association with both (MSNHL) and (SSNHL) but when it was adjusted for 
hearing protection the association dampened and only retained significance in 
(SSNHL). ((MSNHL) OR=2.34 95%CI 1.01-5.38; hearing protection adjusted OR=1.68 
95%CI 0.73-3.87; (SSNHL) OR=8.82 95%CI 2.31-33.64; hearing protection adjusted 
OR=2.88 95%CI 1.00-8.28) (Table 4-3).  
4.3.5 Comparison to NHANES  
The non-tumor hearing thresholds of our patients as well as the NHANES sample all 
maintained normal range hearing of <25 (dB) in the (PTA) throughout all of the age 
groups. Patient’s (PTA) hearing had a statistically lower threshold than NHANES in the 
61-69 age group (mean difference=3.24, p=0.04). Patient’s high tone hearing had a 
statistically lower threshold then NHANES in the 41-50 age group (mean 
difference=4.63, p=0.01). Evidence of (MSNHL) in the high tone hearing thresholds 
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(>25 dB) were seen in the 51-60 and 61-69 age groups for both our patients and the 
NHANES sample.  
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Table 4-5 High Tone Hearing In Non-Tumor Ear Vs. National Average (By Age Group) 
Demographics NHANES28 Non-Tumor Ear 
Total (N=2046)   (N=286) 
Men  893 (48.82%) 166 (51.71%) 
Mean Age (95%CI) 41.91 (41.23-42.59) 52.19 (Std. Dev 10.65) 
Age Groups Mean Low Tone Audiometry29  
in Decibels (dB) 
Mean High Tone Audiometry30  
in Decibels (dB) 
Age <30  Age <30    
NHANES (n used31=495) missing32=38 
Mean (95%CI)       
 
8.55 (7.74-9.37) 
 
11.22(9.54-12.90) 
Non-Tumor  (N=10) 
Mean (StDev) 
 
9.67 (7.73) 
 
8.67 (9.29) 
Age 31-40    Age 31-40   
NHANES (n=401) missing 32 
Mean (95%CI)       
 
9.28(8.50-10.06) 
 
14.61(13-16.21) 
Non-Tumor  (N=30) 
Mean (StDev) 
 
10.83(8.91) 
 
17.61(15.28) 
Age 41-50    Age 41-50   
NHANES (n=414) missing 27 
Mean (95%CI)       
11.63(10.67-12.59) 21.20(19.41-22.99) 
Non-Tumor  (N=70) 
Mean (StDev) 
 
11.02(7.12) 
 
16.57(12.56) 
Age 51-60    Age 51-60   
NHANES (n=332)  missing 18 
Mean (95%CI)       
 
15.66(14.36-16.96) 
 
30.54(27.75-33.33) 
Non-Tumor  (N=110) 
Mean (StDev) 
 
13.73(8.44) 
 
28.73(15.76) 
Age 61-69    Age 61-69   
NHANES (n=272) missing 17 
Mean (95%CI)       
 
21.04(19.10-22.99) 
 
40.96(36.89-45.03) 
Non-Tumor  (N=66) 
Mean (StDev) 
 
17.80(10.20) 
 
35.25(21.01) 
 
                                                 
28 N represents actual number of participants. Percentages are weighted to be representative of the total US 
population. 95% confidence intervals are given 
29 Mean of 0.5, 1, and 2 kHz 
30 Mean of 3, 4, and 6 kHz 
31 Number of observations used in the weighted PROCSURVEY output 
32 Number of observations with non-positive weights 
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4.4 DISCUSSION  
The first reported study of contralateral hearing loss in acoustic neuroma patients was 
published in 1977 and demonstrated abnormal auditory brainstem responses in the 
non-tumor ear. 73Such abnormal findings have been attributed to large acoustic 
neuromas that cause significant compression of the brainstem. 73-75 Our median tumor 
volume was in the small to moderate tumor range (0.5cm3 (range 0.012-17.3)) which 
would not cause compression of the brainstem. Another consequence of large acoustic 
neuromas was found in one study with abnormal caloric tests. Hyperactive contralateral 
responses was also attributed to brainstem compression from large acoustic 
neuromas.76 
A study of electrocochleography in the contralateral ear demonstrated that 25.9% 
of subjects had abnormal negative summating potential to compound action potential 
ratios (–SP/AP).77This finding was not found to be related to the tumor size or 
audiogram thresholds. The author believed that these findings were accurate but gave a 
possible explanation of endolymphatic hydrop formation in the contralateral ear (which 
could have been caused by several factors including inner ear damage, viral infection, 
noise exposure, and head trauma)77 which were not controlled for in their study.   
A Dutch study by Stipkovits et al. (1998) looked at contralateral audiograms at 
0.5, 1, 2, and 4 kHz and c ompared them to an international standard of audiogram 
thresholds (ISO 7029) by age. This study reported that some patients (between 20-
30%) showed contralateral audiometry thresholds that were higher than the 90th 
percentile of the standardized thresholds at each frequency.75The study did not report 
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what the audiogram thresholds are nor did it adjust for the higher proportion of men in 
their analysis (53.8% men vs. 46.2% women).  
Our patients maintained a high speech discrimination score of 95.84% (Gardner 
Robertson 1-2) in the non-tumor ear which would be c lassified as highly functional 
hearing.78Patients who showed evidence of abnormal audiometry such as (MSNHL) or 
(SSNHL) had expected factors for sensorineural hearing decline such as increasing age 
(which is the most common cause of sensorineural hearing loss) and the male gender 
which can be linked to gender specific environmental and occupational exposures as 
well as a military history.79-88These associations can be seen both in our univariate 
analysis and as increased risk in our regression models. We did not find any increased 
risk associated with the practice of loud hobbies. Some of the limitations of our 
subjective data on loud hobbies include: lack of more in depth analysis pertaining to 
frequency of hobby practice (as opposed to only asking about duration) and information 
on whether or not any hearing protection was used during the hobbies.    
Occupational noise exposure also attributed to some of the high tone hearing 
loss seen in our patients. Chronic loud noise exposure is a w ell established risk of 
sensorineural high tone hearing loss.89-92In our comparison of occupational noise 
exposure we found that between groups of similar ages, there was evidence of 
significantly higher hearing thresholds in the high tones consistent with the reported 
occupational loud noise exposure (Table 4-4). We can also see the effect of 
occupational noise exposure adjusted for age and gender on sensorineural hearing loss 
in our regression models. We can even demonstrate the expected shielding effect of 
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hearing protection use on s ensorineural hearing loss when we adjust for it in our 
regression models (Table 4-3). 
The NHANES control group was frequency matched by age and the overall 
gender distribution was near 50% in both groups (NHANES=48.82% men; 
patients=51.7% men). Both our patient sample and the NHANES sample showed 
abnormal hearing thresholds in the high tones in the oldest age groups and our patients 
did not do worse than the NHANES sample in either of those age groups. The two 
groups where our patients showed statistically lower hearing thresholds most likely do 
not represent a clinically significant difference since both hearing levels remain within a 
normal hearing range <25(dB)66 (Table 4-5). 
4.5 CONCLUSIONS 
Acoustic neuroma patients have a very normal level of hearing in the non-tumor ear. 
Despite the devastating effect that the tumor can have on hearing in the affected ear, 
there does not appear to be any negative effect on the contra-lateral hearing. Patients 
have a l evel of hearing in the unaffected ear that is comparable to the normal US 
population as seen when comparing to the NHANES sample. Evidence of sensorineural 
hearing loss in the non-tumor ear of our patients can be explained by established risk 
factors such as advanced age and loud noise exposure. Further research in this area in 
the form of a prospective study to look for changes in audiometry over time would be 
beneficial in order to better understand the effect, if any, of acoustic neuromas on the 
non-tumor ear as well as the effect, if any, of tumor treatment on the unaffected ear. 
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